{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:22:57Z","timestamp":1780521777755,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00428-020-02755-2","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T11:04:05Z","timestamp":1581073445000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders"],"prefix":"10.1007","volume":"477","author":[{"given":"Francesco","family":"Pierconti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Raspollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Francesco","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bientinesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Petracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Maria","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"2755_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer; new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25\u201341","journal-title":"Nat Rev Cancer"},{"key":"2755_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer epidemiology staging and grading and diagnosis. Urology 66:4\u201334","journal-title":"Urology"},{"key":"2755_CR3","first-page":"195","volume":"9","author":"S Albisinni","year":"2017","unstructured":"Albisinni S, Gilsoul J et al (2017) Risk factor assessment in high-risk, bacillus Calmette-Gu\u00e9rin-treated, non-muscle-invasive bladder cancer. Res Rep Urol 9:195\u2013202. 2020-B-01061","journal-title":"Res Rep Urol"},{"key":"2755_CR4","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"38","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA et al (2016) Bladder cancer. Lancet 38:2796\u20132810","journal-title":"Lancet"},{"key":"2755_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH et al (2014) The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 11:153\u2013162","journal-title":"Nat Rev Urol"},{"key":"2755_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.30392","volume":"123","author":"VT Packiam","year":"2017","unstructured":"Packiam VT, Johnson SC, Steinberg GD et al (2017) Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Gu\u00e9rin. Cancer 123:390\u2013400","journal-title":"Cancer"},{"key":"2755_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat AM, Flaig TW, Grossman HB et al (2015) Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12:225\u2013235","journal-title":"Nat Rev Urol"},{"key":"2755_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/184291a0","volume":"184","author":"LJ Old","year":"1959","unstructured":"Old LJ, Clarke DA, Benacerraf B (1959) Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184:291","journal-title":"Nature"},{"key":"2755_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180\u2013183","journal-title":"J Urol"},{"issue":"6","key":"2755_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JW, Dalbagni G, Roupr\u00eat M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J (2012) Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer. Eur Urol 62(6):1088\u20131096","journal-title":"Eur Urol"},{"key":"2755_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP et al (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205\u2013214","journal-title":"Cell"},{"key":"2755_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287","journal-title":"Nat Rev Cancer"},{"issue":"7528","key":"2755_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558\u2013562","journal-title":"Nature"},{"issue":"10031","key":"2755_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920","journal-title":"Lancet"},{"issue":"8","key":"2755_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","volume":"42","author":"A Hodgson","year":"2018","unstructured":"Hodgson A, Slodkowska E, Jungbluth A, Liu SK, Vesprini D, Enepekides D, Higgins K, Katabi N, Xu B, Downes MR (2018) PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol 42(8):1059\u20131066","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2755_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/modpathol.2017.188","volume":"31","author":"M Tretiakova","year":"2018","unstructured":"Tretiakova M, Fulton R, Kocherginsky M et al (2018) Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol 31(4):623\u2013632","journal-title":"Mod Pathol"},{"issue":"6","key":"2755_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00428-018-2453-7","volume":"473","author":"L Zavalishina","year":"2018","unstructured":"Zavalishina L, Tsimafeyeu I, Povilaitite P, Raskin G, Andreeva Y, Petrov A, Kharitonova E, Rumyantsev A, Pugach I, Frank G, Tjulandin S (2018) RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch 473(6):719\u2013724","journal-title":"Virchows Arch"},{"issue":"6","key":"2755_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/his.13710","volume":"73","author":"JJ de Jong","year":"2018","unstructured":"de Jong JJ, Stoop H, Nieboer D, Boormans JL, van Leenders GJLH (2018) Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology 73(6):983\u2013989","journal-title":"Histopathology"},{"issue":"5","key":"2755_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.urolonc.2019.01.002","volume":"37","author":"EF Burgess","year":"2019","unstructured":"Burgess EF, Livasy C, Hartman A et al (2019) Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol 37(5):299 e19-299.e25","journal-title":"Urol Oncol"},{"issue":"10064","key":"2755_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67\u201376","journal-title":"Lancet"},{"issue":"11","key":"2755_CR21","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol 17(11):1590\u20131598","journal-title":"Lancet Oncol"},{"issue":"26","key":"2755_CR22","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S et al (2016) Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34(26):3119\u20133125","journal-title":"J Clin Oncol"},{"issue":"1","key":"2755_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51\u201364","journal-title":"Lancet Oncol"},{"issue":"3","key":"2755_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz J\u00c1, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18(3):312\u2013322","journal-title":"Lancet Oncol."},{"issue":"11","key":"2755_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"10122","key":"2755_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748\u2013757","journal-title":"Lancet"},{"key":"2755_CR27","first-page":"JCO1801148","volume":"20","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 20:JCO1801148","journal-title":"J Clin Oncol"},{"issue":"10","key":"2755_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41585-018-0056-3","volume":"15","author":"T Powles","year":"2018","unstructured":"Powles T, Morrison L (2018) Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma. Nat Rev Urol 15(10):585\u2013587","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2755_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-5347(17)38242-3","volume":"145","author":"CR Herr","year":"1991","unstructured":"Herr CR (1991) Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol 145(1):40\u201343","journal-title":"J Urol"},{"key":"2755_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461","journal-title":"Eur Urol"},{"key":"2755_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/modpathol.2016.186","volume":"30","author":"JA Rehman","year":"2017","unstructured":"Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL (2017) Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol 30:340\u2013349","journal-title":"Mod Pathol"},{"issue":"7528","key":"2755_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013581","journal-title":"Nature"},{"issue":"7528","key":"2755_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577\u2013581","journal-title":"Nature"},{"key":"2755_CR34","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023\u20135039","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2755_CR35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66(5):551\u2013564","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2755_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.5301\/tj.5000326","volume":"101","author":"L Yu","year":"2015","unstructured":"Yu L, Wang Y, Shao S (2015) B7-H1\/PD-1 blockade therapy in urological malignancies: current status and future prospects. Tumori 101(5):549\u2013554","journal-title":"Tumori"},{"issue":"5","key":"2755_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/14737140.2015.1015419","volume":"15","author":"Y Wu","year":"2015","unstructured":"Wu Y, Enting D, Rudman S, Chowdhury S (2015) Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Rev Anticancer Ther 15(5):509\u2013523","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2755_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1586\/14737140.2015.961430","volume":"15","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yang M, Yu Q, Yu L, Shao S, Wang X (2015) Recombinant bacillus Calmette-Gu\u00e9rin in urothelial bladder cancer immunotherapy: current strategies. Expert Rev Anticancer Ther 15(1):85\u201393","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2755_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ et al (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84\u201388","journal-title":"Nat Med"},{"issue":"8","key":"2755_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/2326-6066.CIR-15-0024","volume":"3","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A et al (2015) Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol Res 3(8):855\u2013863","journal-title":"Cancer Immunol Res"},{"key":"2755_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.anndiagpath.2018.12.001","volume":"38","author":"AF Nicol","year":"2019","unstructured":"Nicol AF, de Andrade CV, Gomes SC Jr, Brusadelli MG, Lodin HM, Wells SI et al (2019) The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell carcinoma of the uterine cervix. Ann Diagn Pathol 38:115\u2013122","journal-title":"Ann Diagn Pathol"},{"key":"2755_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalv\u00e9e S, Washetine K, Mouroux J, V\u00e9nissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27:147\u2013153","journal-title":"Ann Oncol"},{"issue":"2","key":"2755_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 12(2):208\u2013222","journal-title":"J Thorac Oncol"},{"key":"2755_CR44","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdy014","volume":"29","author":"J Adam","year":"2018","unstructured":"Adam J, Le Stang N, Rouquette I et al (2018) Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 29:953\u2013958","journal-title":"Ann Oncol"},{"key":"2755_CR45","doi-asserted-by":"publisher","unstructured":"Lawson NL, Dix CI, Scorer PW et al (2019) Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol. https:\/\/doi.org\/10.1038\/s41379-019-0372-z","DOI":"10.1038\/s41379-019-0372-z"},{"key":"2755_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","volume":"66","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90\u2013107","journal-title":"Urology"},{"issue":"8","key":"2755_CR47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109(8):1499\u20131505","journal-title":"Cancer"},{"issue":"3","key":"2755_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00428-013-1378-4","volume":"462","author":"E Comp\u00e9rat","year":"2013","unstructured":"Comp\u00e9rat E, Jacquet SF, Varinot J, Conort P, Roupret M, Chartier-Kastler E, Bitker MO, Witjes JA, Cussenot O (2013) Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. Virchows Arch 462(3):343\u2013348","journal-title":"Virchows Arch"},{"key":"2755_CR49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2003.09.013","volume":"45","author":"JA Witjes","year":"2004","unstructured":"Witjes JA (2004) Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45:142\u2013114","journal-title":"Eur Urol"}],"updated-by":[{"DOI":"10.1007\/s00428-020-02791-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000}}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02755-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-020-02755-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02755-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T14:10:32Z","timestamp":1650204632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-020-02755-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02755-2","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This correction is being done to update the right surname of first name of authors of this manuscript. This does not change the results or the views presented in this manuscript.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}